{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "GBp", "marketState": "POSTPOST", "regularMarketChangePercent": 3.0769231, "regularMarketPrice": 33.5, "exchange": "LSE", "shortName": "REDX PHARMA PLC ORD 1P", "longName": "Redx Pharma Plc", "messageBoardId": "finmb_114713148", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketTime": 1683903165, "earningsTimestamp": 1684321140, "earningsTimestampStart": 1684321140, "earningsTimestampEnd": 1684321140, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.06, "epsForward": -11.9, "epsCurrentYear": -13.7, "priceEpsCurrentYear": -2.4452555, "sharesOutstanding": 334911008, "bookValue": 0.099, "fiftyDayAverage": 34.12, "fiftyDayAverageChange": -0.61999893, "fiftyDayAverageChangePercent": -0.01817113, "twoHundredDayAverage": 51.2905, "twoHundredDayAverageChange": -17.7905, "twoHundredDayAverageChangePercent": -0.3468576, "marketCap": 112195184, "forwardPE": -0.028151263, "priceToBook": 338.38385, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1427443200000, "priceHint": 2, "regularMarketChange": 1.0, "regularMarketDayHigh": 35.0, "regularMarketDayRange": "30.05 - 35.0", "regularMarketDayLow": 30.05, "regularMarketVolume": 1677, "regularMarketPreviousClose": 32.5, "bid": 30.0, "ask": 37.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "LSE", "financialCurrency": "GBP", "regularMarketOpen": 35.0, "averageDailyVolume3Month": 21566, "averageDailyVolume10Day": 29360, "fiftyTwoWeekLowChange": 7.0, "fiftyTwoWeekLowChangePercent": 0.26415095, "fiftyTwoWeekRange": "26.5 - 70.0", "fiftyTwoWeekHighChange": -36.5, "fiftyTwoWeekHighChangePercent": -0.5214286, "fiftyTwoWeekLow": 26.5, "fiftyTwoWeekHigh": 70.0, "symbol": "REDX.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Alderley Park", "address2": "Block 33 Mereside Alderley Edge", "city": "Macclesfield", "zip": "SK10 4TG", "country": "United Kingdom", "phone": "44 16 2546 9900", "website": "https://www.redxpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.", "fullTimeEmployees": 95, "companyOfficers": [{"maxAge": 1, "name": "Ms. Lisa Mary Whewell Anson", "age": 52, "title": "CEO & Exec. Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 636994, "fmt": "636.99k", "longFmt": "636,994"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 822256, "fmt": "822.26k", "longFmt": "822,256"}}, {"maxAge": 1, "name": "Mr. Peter J. Collum", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. James  Mead", "age": 44, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Richard  Armer", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Karl  Hard Ph.D.", "age": 60, "title": "Head of Investor Relations", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Claire  Solk", "title": "Gen. Counsel & Company Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Caitlin  Pearson", "title": "Head of Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jane  Robertson", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Cliff  Jones", "title": "Sr. VP of Chemistry, DMPK & Intellectual Property", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Caroline  Phillips", "title": "Sr. VP of Biology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}